Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Fellow, Hematology, Oncology, Cellular Therpay, Duke University School of Medicine 2007 - 2010
  • M.D., Shanghai Second Medical University (China) 1991
• 

  Duke Appointment History

  • Associate Professor of Medicine, Medicine, Hematologic Malignancies and Cellular Therapy, Medicine 2015 - 2019
  • Instructor Temporary in the Department of Medicine, Medicine, Hematologic Malignancies and Cellular Therapy, Medicine 2014 - 2015
• Research
• 

  Selected Grants

  • Epigenomic Reprogramming in Patient Derived Models of Colorectal Cancer awarded by National Institutes of Health 2018 - 2023
  • PHASE 2 STUDY OF POMALIDOMIDE WITH LOW-DOSE DEXAMETHASONE awarded by Celgene Corporation 2017 - 2022
  • Targeting the p38/Snail/PD-L1 axis in hormone-therapy resistance and metastasis awarded by Department of Defense 2018 - 2021
  • Transfusion Medicine and Hematology awarded by National Institutes of Health 1975 - 2021
  • Effects of PPAR agonists on response to immunomodulatory agents in patients with multiple myeloma awarded by National Institutes of Health 2019 - 2020
  • Clinical characteristics, JAK2 status, and macrophage infiltration in multiple myeloma patients with marrow fibrosis awarded by Incyte Corporation 2017 - 2020
  • Targeting sphingosine kinase 2 for the treatment of multiple myeloma awarded by National Institutes of Health 2015 - 2020
  • Clinical Trial of ABC294640 in Patients with Refractory Multiple Myeloma awarded by Apogee Biotechnology Corporation 2015 - 2019
  • Phase I PVD for Amyloidosis awarded by Karmanos Cancer Center 2014 - 2019
  • Ph III study to evaluate the safety of ALN-TTR02 in TTR-Medicated Polyneuropathy awarded by Alnylam Pharmaceuticals 2014 - 2018
  • Thioredoxin for radioprotection awarded by Columbia University 2016 - 2018
  • Develop and Support of the RedCap database, bio-statistic analysis, and med writing for Dr Kang NIH SBIR award Clin Trial awarded by RedHill Biopharma Ltd. 2016 - 2018
  • Plerixafor for allogeneic hematopoietic stem cell transplantation awarded by National Institutes of Health 2014 - 2016
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Gandhi, UH, Cornell, RF, Lakshman, A, Gahvari, ZJ, McGehee, E, Jagosky, MH, Gupta, R, Varnado, W, Fiala, MA, Chhabra, S, Malek, E, Mansour, J, Paul, B, Barnstead, A, Kodali, S, Neppalli, A, Liedtke, M, Narayana, S, Godby, KN, Kang, Y, Kansagra, A, Umyarova, E, Scott, EC, Hari, P, Vij, R, Usmani, SZ, Callander, NS, Kumar, SK, and Costa, LJ. "Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy." Leukemia (March 11, 2019).  Full Text
    • Rizzieri, D, Paul, B, and Kang, Y. "Metabolic alterations and the potential for targeting metabolic pathways in the treatment of multiple myeloma." Journal of Cancer Metastasis and Treatment 5 (January 2019).  Full Text
    • Zheng, J, Sha, Y, Roof, L, Foreman, O, Lazarchick, J, Venkta, JK, Kozlowski, C, Gasparetto, C, Chao, N, Ebens, A, Hu, J, and Kang, Y. "Pan-PIM kinase inhibitors enhance Lenalidomide's anti-myeloma activity via cereblon-IKZF1/3 cascade." Cancer Letters 440-441 (January 2019): 1-10.  Full Text
    • Paul, B, Kang, S, Zheng, Z, and Kang, Y. "The challenges of checkpoint inhibition in the treatment of multiple myeloma." Cellular Immunology 334 (December 2018): 87-98. (Review)  Full Text
    • Sivaraj, D, Green, MM, Kang, Y, Long, GD, Rizzieri, DA, Li, Z, Garrett, AH, McIntyre, JL, Chao, NJ, and Gasparetto, C. "Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma." Blood Cancer Journal 8, no. 8 (July 31, 2018): 71-null. (Letter)  Full Text
    • Sundaramoorthy, P, Gasparetto, C, and Kang, Y. "The combination of a sphingosine kinase 2 inhibitor (ABC294640) and a Bcl-2 inhibitor (ABT-199) displays synergistic anti-myeloma effects in myeloma cells without a t(11;14) translocation." Cancer Medicine (May 15, 2018).  Full Text
    • Zheng, Z, Fan, S, Zheng, J, Huang, W, Gasparetto, C, Chao, NJ, Hu, J, and Kang, Y. "Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma." Journal of hematology & oncology 11, no. 1 (February 27, 2018): 29-.  Full Text
    • Kumar, SK, Callander, NS, Alsina, M, Atanackovic, D, Biermann, JS, Castillo, J, Chandler, JC, Costello, C, Faiman, M, Fung, HC, Godby, K, Hofmeister, C, Holmberg, L, Holstein, S, Huff, CA, Kang, Y, Kassim, A, Liedtke, M, Malek, E, Martin, T, Neppalli, VT, Omel, J, Raje, N, Singhal, S, Somlo, G, Stockerl-Goldstein, K, Weber, D, Yahalom, J, Kumar, R, and Shead, DA. "NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018." Journal of the National Comprehensive Cancer Network : Jnccn 16, no. 1 (January 2018): 11-20.  Full Text
    • Sivaraj, D, Bacon, W, Long, GD, Rizzieri, DA, Horwitz, ME, Sullivan, KM, Kang, Y, Li, Z, Chao, NJ, and Gasparetto, C. "High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma." Bone Marrow Transplantation 53, no. 1 (January 2018): 34-38.  Full Text
    • Sundaramoorthy, P, Wang, Q, Zheng, Z, Jiao, Y, Chen, BJ, Doan, PL, Chao, NJ, and Kang, Y. "Thioredoxin mitigates radiation-induced hematopoietic stem cell injury in mice." Stem Cell Research & Therapy 8, no. 1 (November 15, 2017): 263-null.  Full Text
    • Tuchman, SA, Moore, JO, DeCastro, CD, Li, Z, Sellars, E, Kang, Y, Long, G, and Gasparetto, CG. "Phase II study of dose-attenuated bortezomib, cyclophosphamide and dexamethasone ("VCD-Lite") in very old or otherwise toxicity-vulnerable adults with newly diagnosed multiple myeloma." Journal of geriatric oncology 8, no. 3 (May 2017): 165-169.  Full Text
    • Sivaraj, D, Green, MM, Li, Z, Sung, AD, Sarantopoulos, S, Kang, Y, Long, GD, Horwitz, ME, Lopez, RD, Sullivan, KM, Rizzieri, DA, Chao, NJ, and Gasparetto, C. "Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma." Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation 23, no. 2 (February 2017): 262-268.  Full Text
    • Green, MMB, Chao, N, Chhabra, S, Corbet, K, Gasparetto, C, Horwitz, A, Li, Z, Venkata, JK, Long, G, Mims, A, Rizzieri, D, Sarantopoulos, S, Stuart, R, Sung, AD, Sullivan, KM, Costa, L, Horwitz, M, and Kang, Y. "Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery." Journal of Hematology & Oncology 9, no. 1 (August 17, 2016): 71-null.  Full Text  Open Access Copy
    • An, N, Cen, B, Cai, H, Song, JH, Kraft, A, and Kang, Y. "Pim1 kinase regulates c-Kit gene translation." Experimental hematology & oncology 5 (January 2016): 31-.  Full Text
    • Schade, H, Chhabra, S, Kang, Y, Stuart, RK, Edwards, KH, Kramer, C, Butcher, C, Littleton, A, Schneider, M, Budisavljevic, MN, and Costa, LJ. "Similar dynamics of intraapheresis autologous CD34+ recruitment and collection efficiency in patients undergoing mobilization with or without plerixafor." Transfusion 54, no. 12 (December 2014): 3131-3137.  Full Text
    • Venkata, JK, An, N, Stuart, R, Costa, LJ, Cai, H, Coker, W, Song, JH, Gibbs, K, Matson, T, Garrett-Mayer, E, Wan, Z, Ogretmen, B, Smith, C, and Kang, Y. "Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma." BLOOD 124, no. 12 (September 18, 2014): 1915-1925.  Full Text  Link to Item
    • Venkata, JK, An, N, Stuart, R, Costa, LJ, Cai, H, Coker, W, Song, JH, Gibbs, K, Matson, T, Garrett-Mayer, E, Wan, Z, Ogretmen, B, Smith, C, and Kang, Y. "Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma." Blood 124, no. 12 (September 2014): 1915-1925.  Full Text
    • Costa, LJ, Nista, EJ, Buadi, FK, Lacy, MQ, Dispenzieri, A, Kramer, CP, Edwards, KH, Kang, Y, Gertz, MA, Stuart, RK, and Kumar, S. "Prediction of Poor Mobilization of Autologous CD34+ Cells with Growth Factor in Multiple Myeloma Patients: Implications for Risk-Stratification." Biology of Blood and Marrow Transplantation 20, no. 2 (February 2014): 222-228.  Full Text
    • An, N, and Kang, Y. "Thioredoxin and hematologic malignancies." Advances in cancer research 122 (January 2014): 245-279.  Full Text
    • Roof, L, Coker, WJ, Lazarchick, J, and Kang, Y. "Senile transthyretin cardiac amyloidosis in patients with plasma cell dyscrasias: importance of cardiac biopsy for making the correct diagnosis." Aperito journal of cellular and molecular biology 1, no. 1 (January 2014).
    • An, N, Janech, MG, Bland, AM, Lazarchick, J, Arthur, JM, and Kang, Y. "Proteomic analysis of murine bone marrow niche microenvironment identifies thioredoxin as a novel agent for radioprotection and for enhancing donor cell reconstitution." Experimental Hematology 41, no. 11 (November 2013): 944-956.  Full Text
    • An, N, Lin, Y-W, Mahajan, S, Kellner, JN, Wang, Y, Li, Z, Kraft, AS, and Kang, Y. "Pim1 Serine/Threonine Kinase Regulates the Number and Functions of Murine Hematopoietic Stem Cells." STEM CELLS 31, no. 6 (June 2013): 1202-1212.  Full Text
    • Zhou, D, Deoliveira, D, Kang, Y, Choi, SS, Li, Z, Chao, NJ, and Chen, BJ. "Insulin-like growth factor 1 mitigates hematopoietic toxicity after lethal total body irradiation." International Journal of Radiation Oncology, Biology, Physics 85, no. 4 (March 2013): 1141-1148.  Full Text
    • An, N, Kraft, AS, and Kang, Y. "Abnormal hematopoietic phenotypes in Pim kinase triple knockout mice." Journal of Hematology & Oncology 6, no. 1 (2013): 12-12.  Full Text
    • Coker, WJ, Jeter, A, Schade, H, and Kang, Y. "Plasma cell disorders in HIV-infected patients: epidemiology and molecular mechanisms." Biomarker Research 1, no. 1 (2013): 8-8.  Full Text
    • Kellner, J, Liu, B, Kang, Y, and Li, Z. "Fact or fiction - identifying the elusive multiple myeloma stem cell." Journal of Hematology & Oncology 6, no. 1 (2013): 91-91.  Full Text
    • Butler, C, Wolff, DJ, Kang, Y, Stuart, RK, and Costa, LJ. "Association of age with fluorescence in situ hybridization abnormalities in multiple myeloma reveals higher rate of IGH translocations among older patients." Leukemia & Lymphoma 53, no. 12 (December 2012): 2444-2448.  Full Text
    • Jeter, A, and Kang, Y. "Immune modulation therapy in the management of bortezomib-induced peripheral neuropathy." Experimental Hematology & Oncology 1, no. 1 (December 2012).  Full Text
    • Costa, LJ, Abbas, J, Hogan, KR, Kramer, C, McDonald, K, Butcher, CD, Littleton, A, Shoptaw, K, Kang, Y, and Stuart, RK. "Growth factor plus preemptive (‘just-in-time’) plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure." Bone Marrow Transplantation 47, no. 11 (November 2012): 1403-1408.  Full Text
    • Costa, LJ, Abbas, J, Ortiz-Cruz, KL, Kang, Y, and Stuart, RK. "Outcomes of patients with multiple myeloma and renal impairment treated with bortezomib, cyclophosphamide, and dexamethasone without plasma exchange." European Journal of Haematology 89, no. 5 (November 2012): 432-434.  Full Text
    • Costa, LJ, Kramer, C, Hogan, KR, Butcher, CD, Littleton, AL, Shoptaw, KB, Kang, Y, and Stuart, RK. "Pegfilgrastim- versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis." Transfusion 52, no. 11 (November 2012): 2375-2381.  Full Text
    • Kang, Y, Chen, BJ, Deoliveira, D, Mito, J, and Chao, NJ. "Selective enhancement of donor hematopoietic cell engraftment by the CXCR4 antagonist AMD3100 in a mouse transplantation model." PLoS ONE 5, no. 6 (2010).  Full Text  Open Access Copy
    • Kang, Y, Chao, NJ, and Aversa, F. "Unmanipulated or CD34 selected haplotype mismatched transplants." Current Opinion in Hematology 15, no. 6 (2008): 561-567.  Full Text
    • Kang, Y, Moressi, CJ, Scheetz, TE, Xie, L, Tran, DT, Casavant, TL, Ak, P, Benham, CJ, Davidson, BL, and McCray, PB. "Integration Site Choice of a Feline Immunodeficiency Virus Vector." Journal of Virology 80, no. 17 (September 1, 2006): 8820-8823.  Full Text
    • Kang, Y. "Persistent expression of factor VIII in vivo following nonprimate lentiviral gene transfer." Blood 106, no. 5 (September 1, 2005): 1552-1558.  Full Text
    • Song, L, Wang, J, Wang, R, Yu, M, Sun, Y, Han, G, Li, Y, Qian, J, Scott, DW, Kang, Y, Soukhareva, N, and Shen, B. "Retroviral delivery of GAD-IgG fusion construct induces tolerance and modulates diabetes: a role for CD4+ regulatory T cells and TGF-β?." Gene Therapy 11, no. 20 (October 2004): 1487-1496.  Full Text
    • Starner, TD, Barker, CK, Jia, HP, Kang, Y, and McCray, PB. "CCL20 Is an Inducible Product of Human Airway Epithelia with Innate Immune Properties." American Journal of Respiratory Cell and Molecular Biology 29, no. 5 (November 2003): 627-633.  Full Text
    • Kang, Y, Stein, CS, Heth, JA, Sinn, PL, Penisten, AK, Staber, PD, Ratliff, KL, Shen, H, Barker, CK, Martins, I, Sharkey, CM, Sanders, DA, McCray, PB, and Davidson, BL. "In Vivo Gene Transfer Using a Nonprimate Lentiviral Vector Pseudotyped with Ross River Virus Glycoproteins." Journal of Virology 76, no. 18 (September 15, 2002): 9378-9388.  Full Text
    • Melo, MEF, Qian, J, El-Amine, M, Soukhareva, N, Kang, Y, and Scott, DW. "Gene transfer of immunoglobulin-fusion proteins prevents and treats autoimmune diseases." J. Immunol 168, no. 9 (2002): 4788-4795.
    • Stein, CS, Kang, Y, Sauter, SL, Townsend, K, Staber, P, Derken, TA, Martins, I, Qian, J, Davidson, BL, and McCray, PB. "In vivo treatment of hemophilia A and mucopolysaccharidosis type VII using non-primate lentiviral vectors." Molecular Therapy 3 (2001): 850-856.
    • Agarwal, RK, Kang, Y, Zambidis, E, Scott, DW, Chan, C-C, and Caspi, RR. "Retroviral gene therapy with an immunoglobulin-antigen fusion construct protects from experimental autoimmune uveitis." Journal of Clinical Investigation 106, no. 2 (July 15, 2000): 245-252.  Full Text
    • El-Amine, M, Melo, MEF, Kang, Y, Qian, J, and Scott, DW. "Mechanisms of tolerance induction by an Ig-peptide molecule expressed and secreted by B cells." Journal of immunology (Baltimore, Md. : 1950) 165 (2000): 5631-5636.
    • Kang, Y, Melo, M, Deng, E, Tisch, R, El-Amine, M, and Scott, DW. "Induction of hyporesponsiveness to intact foreign protein via retroviral-mediated gene expression: The IgG scaffold is important for induction and maintenance of immune hyporesponsiveness." Proceedings of the National Academy of Sciences 96, no. 15 (July 20, 1999): 8609-8614.  Full Text
    • Kang, Y, Melo, MEF, and Scott, DW. "An Ongoing Immune Response to HIV Envelope gp120 in Human CD4 Transgenic Mice Contributes to T Cell Decline upon Intravenous Administration of gp120." European Journal of Immunology 28 (1998): 2253-2264.
    • Kang, Y, Edwards, LG, and Thornalley, PJ. "Effect of methylglyoxal on human leukaemia 60 cell growth: Modification of DNA, G1 growth arrest and induction of apoptosis." Leukemia Research 20, no. 5 (May 1996): 397-405.  Full Text
    • Thornalley, PJ, Edwards, LG, Kang, Y, Wyatt, C, Davies, N, Ladan, MJ, and Double, J. "Antitumour activity of S-p-bromobenzylglutathione cyclopentyl diester in vitro and in vivo. Inhibition of glyoxalase I and induction of apoptosis." Biochemical Pharmacology 51, no. 10 (May 1996): 1365-1372.  Full Text
    • Thornalley, PJ, Ladan, M, Ridgeway, S, and Kang, Y. "Anti-tumor Activity of S-(p-bromobenzyl)glutathione Diesters in vitro: a Structure-Activity Study." Journal of Medicinal Chemistry 39, no. 17 (1996): 3409-3411.
    • Huang, LA, Cheng, QS, Kang, Y, and Li, YH. "Cytomegalovirus Infection in Bone Marrow Transplant Patients with Acute Radiation Sickness." Edited by BT Liu and GY Ye. (1994): 315-319.
    • Huang, LA, Meng, PL, Kang, Y, Cheng, QS, and Liu, BT. "Clinical Observation and Prevention of Coagulation Abnormality in 7 Cases of Patients with Acute Radiation Sickness." Edited by BT Liu and GY Ye. (1994): 348-356.
    • Kang, Y, Gu, CN, Meng, PL, Cao, LX, and Huang, LA. "Monitoring of Blood Cyclosporine A Concentration and Clinical Observation in Patients with HLA-semimatched Bone Marrow Transplantation." Edited by BT Liu and GY Ye. (1994): 402-409.
    • Kang, Y, Zing, SW, Meng, PL, Cao, LX, and Huang, LA. "Capillary Leakage Syndrome Associated with Acute Radiation Disease." Edited by BT Liu and GY Ye. (1994): 311-314.
    • Kang, Y, Yu, RQ, and Kong, XT. "Tumor Cell Surface Markers and Differentiation on Multiple Myeloma." Chinese Journal of Hematology 7 (1992): 384-387. (Review)
    • Kang, Y, and Yu, RQ. "Hypertension Associated with Cyclosporine A Treatment in Bone Marrow Transplantation." Foreign Medicine (Blood Transfusion & Hematology) 5 (1991): 288-291. (Review)
    • Kang, Y, and Yu, RQ. "Therapeutic Progress in Multiple Myeloma." Foreign Medicine (Blood Transfusion & Hematology) 3 (1990): 140-143. (Review)
    • An, N, and Kang, Y. "Using Quantitative Real-time PCR to Determine Donor Cell Engraftment in a Competitive Murine Bone Marrow Transplantation Model(Published online)." Journal of Visualized Experiments , no. 73.  Full Text

  • Book Sections

    • Kang, Y, and Chao, NJ. "Strategies to enhance hematopoietic stem cell engraftment following transplantation." In Novel Developments in Stem Cell Mobilization: Focus on CXCR4, 439-456. January 1, 2012.  Full Text
    • Kang, Y, and Chao, N. "Immune reconstitution." In Hematopoietic Stem Cell Transplantation A Handbook for Clinicians, edited by JR Wingard, D Gastineau, H Leather, EC Snyder, and ZM Szczepiokowski, 181-196. Bethesda, MD: AABB Press, 2010. (Chapter)
    • Kang, Y, and Cheng, YB. "A Handbook of Human Cytokines." In Interleukin-3, edited by J He and DX Wang, 79-96. China: Tong Zi University Press, 1996. (Chapter)
    • Kang, Y, and He, J. "Interleukin-4." In A Handbook of Human Cytokines, edited by J He and DX Wang, 97-112. China: Tong Zi University Press, 1996. (Chapter)

  • Digital Publications

    • An, N, and Kang, Y. "In vivo BrdU Incorporation Assay for Murine Hematopioetic Stem Cells." (2013).  Link to Item

  • Conference Papers

    • Kang, Y, Fan, S, Sundaramoorthy, P, Gasparetto, C, Long, G, Garrett, A, Sellars, E, Mcintyre, J, Maines, L, Ben-Yair, VK, Smith, C, and Plasse, T. "Sphingosine kinase 2 (SK2) targeting in the treatment of multiple myeloma: preclinical and phase I studies of opaganib, an SK 2 inhibitor, in multiple myeloma." 30th EORTC-NCI-AACR Symposium. Dublin, IRELAND. November 13, 2018 - November 16, 2018.: ELSEVIER SCI LTD, November 1, 2018.  Link to Item
    • Sung, AD, de Castro, CM, LeBlanc, TW, Long, GD, Adams, DB, Brander, DM, Dave, S, Diehl, LF, Phuong, LD, Hennig, T, Kang, Y, McKinney, MS, Rein, LAM, Sipkins, DA, Yang, Y, Chao, NJ, and Rizzieri, DA. "Clinical Outcomes of Microtransplantation for Older Adults with Acute Myeloid Leukemia." 59th Annual Meeting of the American-Society-of-Hematology (ASH). Atlanta, GA. December 9, 2017 - December 12, 2017.: AMER SOC HEMATOLOGY, December 7, 2017.  Link to Item
    • Sivaraj, D, Green, MM, Kang, Y, Rizzieri, D, Diehl, LF, Beaven, AW, Li, Z, Garrett, A, McIntyre, J, Long, GD, Chao, NJA, and Gasparetto, C. "Phase I/II dose expansion of a trial investigating bendamustine and pomalidomide with dexamethasone (BPd) in patients with relapsed/refractory multiple myeloma." : American Society of Clinical Oncology (ASCO), May 20, 2017.  Full Text
    • Gasparetto, C, Green, M, Srinivasan, A, Kang, Y, Rizzieri, DA, Decastro, C, Diehl, LF, Beaven, A, Li, Z, Rao, AV, Garrett, A, Tuchman, S, and Long, GD. "A Phase I-II Study of the Combination of Bendamustine and Pomalidomide with Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma." December 3, 2015.  Link to Item
    • Green, MMB, Horwitz, ME, Kang, Y, Chao, NJ, Long, GD, Rizzieri, D, Gasparetto, C, Sung, AD, Sarantopoulos, S, Li, Z, Corbet, K, Riggan-Stuelke, E, Sullivan, K, Wilson, B, Chhabra, S, Costa, LV, Mims, A, and Stuart, R. "Administration of Plerixafor (a CXCR4 antagonist) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Enhances Platelet Recovery in a Phase I/II Trial." : Elsevier BV, February 2015.  Full Text
    • Zhou, D, Deoliveira, D, Kang, Y, Choi, SS, Chao, NJ, and Chen, BJ. "Insulin-Like Growth Factor 1 Mitigates Hematopoietic Toxicity After Lethal Total Body Irradiation." : Elsevier BV, February 2013.  Full Text
    • An, N, Im, Y-B, Lin, Y, Gasparetto, C, Costa, LJ, Stuart, RK, Smith, C, Kraft, A, and Kang, Y. "Characterization of Pim Protein Kinases and Evaluation of Small Molecule Inhibitors in Multiple Myeloma." November 18, 2011.  Link to Item

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.